The MarketWatch News Department was not involved in the creation of this content.-- Multi-year agreement launches newly titled DuraMAX Grand Prix at the Circuit of The Americas in ...

We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare ...

In the latest weekly data update, Eli Lilly's quality score advanced from 89.66 to 90.04. This uptick pushes the stock into the “elite” tier of the market, ranking it higher than 90% of its peers.

In the latest trading session, Eli Lilly (LLY) closed at $1,056.88, marking a +1.45% move from the previous day. This move outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk. Eli Lilly is increasingly reliant on its GLP-1 drugs. 10 ...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...